ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos2.14 B1.58 B1.71 B1.79 B2.18 B1.62 B7.3 BInvestigación y desarrollo3.19 B2.26 B2.58 B2.53 B2.59 B2.65 B10.34 BBeneficio operativo175 M2.97 B1.77 B3.11 B1.47 B3.24 B9.6 BTotal de ingresos no operativos-849 M-348 M-400 M641 M578 M364 M1.18 BGastos por intereses, netos de intereses capitalizados496 M494 M485 M480 M432 M411 M1.81 BIngresos no operativos, una vez deducidos los gastos por intereses-1.04 B-503 M-391 M53 M95 M-15 M-258 MIngresos/gastos extraordinarios-305 M-339 M-494 M108 M51 M-32 M-367 MBeneficio antes de impuestos175 M2.97 B1.77 B3.11 B1.47 B3.24 B9.6 BParticipación en los beneficios8 M-9 M-37 M-6 M99 M25 M81 MImpuestos99 M509 M460 M919 M384 M561 M2.32 BParticipación minoritaria———————Otros ingresos/gastos después de impuestos29 M-10 M7 M74 M-308 M-21 M-248 MBeneficio neto antes de actividades interrumpidas72 M2.46 B1.31 B2.2 B1.09 B2.68 B7.28 BOperaciones suspendidas———————Beneficio neto72 M2.46 B1.31 B2.2 B1.09 B2.68 B7.28 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas72 M2.46 B1.31 B2.2 B1.09 B2.68 B7.28 BBeneficio básico por acción0.051.210.641.080.541.313.57Beneficio por acción diluido0.051.20.641.080.541.313.57Número medio de acciones ordinarias2.03 B2.03 B2.04 B2.04 B2.03 B2.04 B—Acciones diluidas2.03 B2.04 B2.04 B2.04 B2.04 B2.05 B—EBITDA2.06 B3.98 B2.78 B4.13 B2.45 B3.83 B13.19 BEBIT175 M2.97 B1.77 B3.11 B1.47 B3.24 B9.6 BCosto de los ingresos4.81 B3.03 B3.37 B3.44 B4.1 B3.42 B14.32 BOtros costes de producción———————Amortización y depreciación (flujo de caja)1.88 B1.01 B1.01 B1.01 B977 M594 M3.59 B
Bristol-Myers Squibb Company Common Stock
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.